logo
  • Home
  • Company
    • Management
    • Board of Directors
    • Governance
    • Medical and Scientific Advisory Board
  • Investors
    • Overview
    • News / Events
    • Shareholder Calls / Presentations
    • Company Information
    • Financial Information
    • Stock Data
    • SEC Filings
    • Corporate Governance
  • News & Media
    • Press Releases
    • Articles
    • Reports
    • Media
    • Photo Gallery
  • Contact
    • Social Media Community Guidelines

Press Releases

Navigation Toggle Navigation
  • Overview
  • News / Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Shareholder Calls / Presentations
  • Company Information
  • Financial Information
  • Stock Data
  • SEC Filings
  • Corporate Governance
  • Quick Links
  • Email Alerts
  • Tear Sheet
  • Contacts
  • RSS News Feed
  • All News
  • 2024
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • Dec 27, 2016

PharmaCyte Biotech’s Cannabinoid Therapy May Offer Potential for Childhood Brain Cancers

  • Dec 15, 2016

PharmaCyte Biotech Submits Pre-IND Meeting Package to FDA

  • Dec 12, 2016

PharmaCyte Biotech Secures Funding Opportunity for Pancreatic Cancer Clinical Trial

  • Dec 7, 2016

PharmaCyte Biotech Discusses Upcoming Clinical Trial in Pancreatic Cancer with First Principal Investigator

  • Dec 1, 2016

PharmaCyte Biotech Moves Closer to Enrolling Patients in Pancreatic Cancer Clinical Trial

  • Nov 29, 2016

PharmaCyte Biotech Granted FDA Pre-IND Meeting for Pancreatic Cancer Therapy

  • Nov 16, 2016

PharmaCyte Biotech Now Awaits U.S. FDA to Advance Pancreatic Cancer Therapy into Pivotal Clinical Trial

  • Nov 14, 2016

University of Northern Colorado Presenting PharmaCyte Biotech’s Cannabis Research at the 2017 American Chemical Society National Meeting

  • Nov 1, 2016

PharmaCyte Biotech Requests Pre-IND Meeting with FDA for its Pancreatic Cancer Clinical Trial

  • Oct 24, 2016

PharmaCyte Biotech Selects Dr. Manuel Hidalgo as Principal Investigator for Its Pancreatic Cancer Clinical Trial

RSS
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next »

Contact Us

PharmaCyte Biotech, Inc.
3960 Howard Hughes Parkway, Suite 500
Las Vegas, Nevada 89169
Office Number: 917.595.2850
Facsimile Number: 917.595.2851
Email: info@PharmaCyte.com

Latest News

  • PharmaCyte Biotech Makes $7 Million Strategic Investment in MyMD, A Biopharmaceutical Company Focused on Inflammatory Disease May 21, 2024
  • PharmaCyte Biotech Acquires $5 Million Stake in Emerging Women’s Health Innovator Femasys, Inc. November 15, 2023